Physician profile
Robert W Morrow
NPI 1295747137
$619.17
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $132 · 2021: $12.28 · 2022: $24.61 · 2023: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $114.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $101.94 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $97.02 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $82.52 | 2019-2021 | |
| Pfizer INC. | $70.79 | 2019-2020 | |
| Abbott Laboratories | $61.97 | 2019-2023 | Freestyle Libre 2 |
| Amgen INC. | $47.50 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.36 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $25.64 | 2019 | |
| Lilly USA, LLC | $24.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.43 | 2019-2020 | |
| Exact Sciences Corporation | $14.66 | 2023 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $14.33 | 2019 | |
| Merck Sharp & Dohme LLC | $13.61 | 2023 | Vaxneuvance, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.